This event is archived. Final snapshot from when the story concluded. View on Dashboard
Events / Business / Nancy L. Lewis named NCCN CSO
Business leadership appointment

Nancy L. Lewis named NCCN CSO

Analysis based on 7 articles · First reported Apr 09, 2026 · Last updated Apr 09, 2026

Sentiment
20
Attention
2
Articles
7
Market Impact
General
Live prominence charts, article sentiment distribution, and event development timeline available on the Ergen Dashboard
Market Impact

The appointment of Nancy L. Lewis as CSO for the National Comprehensive Cancer Network is a positive development for the healthcare and pharmaceutical industries, as her expertise is expected to advance cancer research and clinical trials. This could lead to improved cancer care and potential breakthroughs, benefiting companies involved in oncology.

pharmaceuticals healthcare
Event Summary

The National Comprehensive Cancer Network (NCCN) announced the appointment of Nancy L. Lewis, MD, MBS, FACP, as its new Chief Scientific Officer (CSO), effective May 2026. Dr. Lewis, an accomplished biomedical researcher with expertise in clinical trials for solid tumors and hematologic malignancies, previously served as Senior Clinical Program Leader for Novartis Pharmaceuticals. In her new role, she will oversee NCCN's programs to advance clinical trials, improve cancer care quality, and manage key initiatives like the NCCN Oncology Research Program and NCCN Clinical Practice Guidelines in Oncology. Crystal S. Denlinger, CEO of NCCN, highlighted Dr. Lewis's importance in fostering innovation and knowledge discovery in cancer research.

Entities Involved
per
Nancy L. Lewis
Nancy L. Lewis has been named the new Chief Scientific Officer for the National Comprehensive Cancer Network, bringing her expertise in biomedical research and clinical trials to oversee key programs.
Importance 100.0 Sentiment 30.0
ngo
National Comprehensive Cancer Network
The National Comprehensive Cancer Network announced the selection of Nancy L. Lewis as its new Chief Scientific Officer, which is expected to advance its programs in clinical trials and cancer care.
Importance 100.0 Sentiment 20.0
per
Crystal S. Denlinger
Crystal S. Denlinger, CEO of the National Comprehensive Cancer Network, expressed confidence in Nancy L. Lewis's appointment and her ability to advance cancer research.
Importance 20.0 Sentiment 0.0
stock
Novartis
Importance 0.0 Sentiment 0.0
ERGEN INTELLIGENCE
Track this event live

Set up alerts, explore entity relationships, search across thousands of events, and build custom intelligence feeds.

Open Dashboard

About Ergen

Ergen is a news intelligence platform that converts raw news articles into structured data. It tracks events, entities, and the relationships between them, with sentiment and attention metrics derived from thousands of articles. Pages on this site are daily static snapshots from the platform's live database. For real-time tracking, search, and alerts, the full dashboard is at app.ergen.ai.